1428308-09-1

Basic information

• Product Name: tert-butyl [7-(3-methoxyphenoxy)-1-oxo-1,2,4,5-tetrahydro[1,2,4]triazolo[4,3-a]quinolin-4-yl]carbamate
• Synonyms: tert-butyl [7-(3-methoxyphenoxy)-1-oxo-1,2,4,5-tetrahydro[1,2,4]triazolo[4,3-a]quinolin-4-yl]carbamate
• CAS NO: 1428308-09-1
• Molecular Weight: 424.456
• Mol File: 1428308-09-1.mol

Chemical Properties

• CAS DataBase Reference: tert-butyl [7-(3-methoxyphenoxy)-1-oxo-1,2,4,5-tetrahydro[1,2,4]triazolo[4,3-a]quinolin-4-yl]carbamate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-butyl [7-(3-methoxyphenoxy)-1-oxo-1,2,4,5-tetrahydro[1,2,4]triazolo[4,3-a]quinolin-4-yl]carbamate(1428308-09-1)
• EPA Substance Registry System: tert-butyl [7-(3-methoxyphenoxy)-1-oxo-1,2,4,5-tetrahydro[1,2,4]triazolo[4,3-a]quinolin-4-yl]carbamate(1428308-09-1)

Safety Data

• Hazardous Substances Data: 1428308-09-1(Hazardous Substances Data)

Upstream product

• 1428308-07-9 tert-butyl [6-(3-methoxyphenoxy)-2-(methylsulfanyl)-3,4-dthydroquinolin-3-yl]carbamate 
• 150-19-6 O-methylresorcine 
• 1428308-08-0 ethyl 2-{3-[(tert-butoxycarbonyl)amino]-6-(3-methoxyphenoxy)-3,4-dihydroquinolin-2(1H)-ylidene}hydrazinecarboxylate 
• 1428308-05-7 tert-butyl [(3R)-6-(3-methoxyphenoxy)-2-thioxo-1,2,3,4-tetrahydroquinolin-3-yl]carbamate 
• 1428308-06-8 tert-butyl [(3R)-6-(3-methoxyphenoxy)-2-oxo-1,2,3,4-tetrahydroquinolin-3-yl]carbamate 
• 1428308-03-5 2-bromo-4-(3-methoxyphenoxy)anillne 
• 1428308-04-6 2-bromo-4-(3-methoxyphenoxy)-1-nitrobenzene 
• 700-36-7 2-bromo-4-fluoronitrobenzene 

Downstream Products

• 1428308-10-4 C₁₇H₁₆N₄O₃ 

Relevant articles and documents

TRICYCLIC COMPOUNDS AS KAT II INHIBITORS

Compounds of Formula (I), wherein R1, R 2, X1, Y1, Z1, and Z2 are as defined herein, and pharmaceutically acceptable salts thereof, are described as useful for the treatment of cognitive deficits associated with schizophrenia and other psychiatric, neurodegenerative and/or neurological disorders in mammals, including humans.

Discovery of hydroxamate bioisosteres as KAT II inhibitors with improved oral bioavailability and pharmacokinetics

A series of kynurenine aminotransferase II (KAT II) inhibitors has been developed replacing the hydroxamate motif with a bioisostere. Triazolinones or triazoles have proven to be effective replacements with significantly improved pharmacokinetics includin